Literature DB >> 9183232

The sequelae of herpes zoster.

K Galil1, P W Choo, J G Donahue, R Platt.   

Abstract

BACKGROUND: The last 40 years was a period during which the incidence of herpes zoster appears to have increased substantially.
OBJECTIVE: To determine whether the risk of complications of herpes zoster has changed during the last 40 years.
METHODS: The automated medical records of a health maintenance organization were screened for diagnosis codes suggesting herpes zoster and potentially complicated cases of zoster. The predictive value of a herpes zoster diagnosis was calculated from sampling full-text records. Records of all patients with codes suggesting complications were reviewed in full.
RESULTS: Of 859 individuals with herpes zoster who met the eligibility criteria, 101 were identified who experienced at least 1 complication, corresponding to a 60-day risk of 12%. Corrected for the sensitivity of the complication-finding strategy, the risk estimate was 14%. Risk increased markedly with age, with those older than 64 years having more than 6 times the risk of complications of those younger than 25 years (odds ratio, 8.3; 95% confidence interval, 2.5-29.3). Trigeminal distribution of rash and the presence of certain conditions associated with immune compromise appeared to increase risk.
CONCLUSIONS: The apparent increase in the incidence of herpes zoster was not accompanied by a change in the risk of specific or overall complications in a population-based sample. Advanced age and other conditions associated with waning cellular immunity may confer an increased risk of experiencing a complicated course of herpes zoster.

Entities:  

Mesh:

Year:  1997        PMID: 9183232

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  32 in total

1.  Clinical diagnosis of herpes zoster in family practice.

Authors:  Wim Opstelten; Anton M van Loon; Margje Schuller; Albert J M van Wijck; Gerrit A van Essen; Karel G M Moons; Theo J M Verheij
Journal:  Ann Fam Med       Date:  2007 Jul-Aug       Impact factor: 5.166

Review 2.  Treatment of herpes zoster.

Authors:  Wim Opstelten; Just Eekhof; Arie Knuistingh Neven; Theo Verheij
Journal:  Can Fam Physician       Date:  2008-03       Impact factor: 3.275

3.  Influence of systemic immune and cytokine responses during the acute phase of zoster on the development of postherpetic neuralgia.

Authors:  Sheng-mei Zhu; Yong-min Liu; Er-dan An; Qing-lian Chen
Journal:  J Zhejiang Univ Sci B       Date:  2009-08       Impact factor: 3.066

Review 4.  A critical appraisal of 'Shingrix', a novel herpes zoster subunit vaccine (HZ/Su or GSK1437173A) for varicella zoster virus.

Authors:  Tehmina Bharucha; Damien Ming; Judith Breuer
Journal:  Hum Vaccin Immunother       Date:  2017-04-20       Impact factor: 3.452

5.  Acute/subacute herpes zoster: healthcare resource utilisation and costs in a group of US health plans.

Authors:  Ralph P Insinga; Robbin F Itzler; James M Pellissier
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

Review 6.  Tolerability of treatments for postherpetic neuralgia.

Authors:  Mark W Douglas; Robert W Johnson; Anthony L Cunningham
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

7.  Herpes zoster among persons living with HIV in the current antiretroviral therapy era.

Authors:  Leah J Blank; Michael J Polydefkis; Richard D Moore; Kelly A Gebo
Journal:  J Acquir Immune Defic Syndr       Date:  2012-10-01       Impact factor: 3.731

8.  Incidence of herpes zoster ophthalmicus: results from the Pacific Ocular Inflammation Study.

Authors:  Durga S Borkar; Vivien M Tham; Elizabeth Esterberg; Kathryn J Ray; Aleli C Vinoya; John V Parker; Aileen Uchida; Nisha R Acharya
Journal:  Ophthalmology       Date:  2012-12-01       Impact factor: 12.079

9.  Vaccination against Herpes Zoster and Postherpetic Neuralgia.

Authors:  Michael N Oxman; Myron J Levin
Journal:  J Infect Dis       Date:  2008-03-01       Impact factor: 5.226

10.  Burden of herpes zoster requiring hospitalization in Spain during a seven-year period (1998-2004).

Authors:  Angel Gil; Ruth Gil; Alejendro Alvaro; María San Martín; Antonio González
Journal:  BMC Infect Dis       Date:  2009-05-07       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.